1.
Pradines J, Rudolph-Owen L, Hunter J, et al. Detection of activity centers in cellular pathways using transcript profiling. J Biopharm Stat. 2004;14(3):701-21. doi:10.1081/BIP-200025678.
1.
Merkle FT, Ghosh S, Kamitaki N, et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature. 2017;545(7653):229-233. doi:10.1038/nature22312.
1.
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50. doi:10.1073/pnas.0506580102.
1.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-25. doi:10.1038/nature11404.
1.
Monti S, Chapuy B, Takeyama K, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012;22(3):359-72. doi:10.1016/j.ccr.2012.07.014.
1.
Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013;31(23):2927-35. doi:10.1200/JCO.2012.48.5052.
1.
Ichida JK, TCW J, Williams LA, et al. Notch inhibition allows oncogene-independent generation of iPS cells. Nat Chem Biol. 2014;10(8):632-639. doi:10.1038/nchembio.1552.
1.
Xue W, Chen S, Yin H, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014;514(7522):380-4. doi:10.1038/nature13589.
1.
Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015;372(26):2481-98. doi:10.1056/NEJMoa1402121.
1.
Townsend EC, Murakami MA, Christodoulou A, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016;29(4):574-86. doi:10.1016/j.ccell.2016.03.008.